Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | HTR1A | P08908 | 3/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25607591 | 0.86 | LMNA (0.63) | LMNAHTR1ADRD2HTR2AALDH1A1 | |
| SCHEMBL12040648 | 0.85 | ALDH1A1 (0.57) | LMNAHTR1ADRD2HTR2AALDH1A1 | |
| SCHEMBL4256046 | 0.84 | DRD2 (0.60) | LMNAHTR1ADRD2HTR2AALDH1A1 | |
| SCHEMBL1724434 | 0.82 | DRD2 (0.49) | LMNAHTR1ADRD2HTR2AALDH1A1 | |
| SCHEMBL1725203 | 0.82 | LMNA (0.56) | LMNAHTR1ADRD2HTR2AALDH1A1 | |
| SCHEMBL4865184 | 0.81 | HTR6 (0.62) | LMNAHTR1ADRD2ALDH1A1SMN1; SMN2 | |
| SCHEMBL1642194 | 0.81 | ALDH1A1 (0.68) | LMNAALDH1A1MAPTMAPK1MEN1 | |
| SCHEMBL311018 | 0.79 | ALDH1A1 (0.47) | LMNAHTR1AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL1815442 | 0.78 | SIRT6 (0.61) | LMNAHTR1AALDH1A1MAPTKMT2A | |
| SCHEMBL309959 | 0.78 | ALDH1A1 (0.44) | LMNAHTR1AALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971606-B1 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2406234-A1 | THIAZOLE SULFONAMIDE AND OXAZOLE SULFONAMIDE KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20110319392-A1 | Thiazole Sulfonamide And Oxazole Sulfonamide Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-12-29 | — | — | US | disclosed |
| US-20110319392-A1 | Thiazole Sulfonamide And Oxazole Sulfonamide Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-12-29 | — | — | US | disclosed |
| US-7807673-B2 | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807673-B2 | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-10-05 | — | — | US | disclosed |
| WO-2010104899-A1 | THIAZOLE SULFONAMIDE AND OXAZOLE SULFONAMIDE KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-09-16 | — | — | WO | disclosed |
| US-20090149456-A1 | 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2009-06-11 | — | — | US | disclosed |
| US-20090149456-A1 | 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2009-06-11 | — | — | US | disclosed |
| EP-1971606-A2 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007067506-A2 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007067506-A2 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149456-A1 | 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors | ERBB2, ERBB3, ERBB4 | LMNA 4786/4885HTR1A 3035/4885DRD2 2095/4885 |
| US-20110319392-A1 | Thiazole Sulfonamide And Oxazole Sulfonamide Kinase Inhibitors | STK24, MAP3K5, MAP3K2 | LMNA 4106/4885HTR1A 4320/4885DRD2 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.